<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05007288</url>
  </required_header>
  <id_info>
    <org_study_id>20200939</org_study_id>
    <nct_id>NCT05007288</nct_id>
  </id_info>
  <brief_title>Restorative Eye Treatment and INhance in Upper Eyelid Blepharoplasty Surgery</brief_title>
  <official_title>A Single Center Evaluation of Restorative Eye Treatment and Inhance With Trihex Technology Effects on the Aesthetic Outcomes When Used Pre and Post Upper Blepharoplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to determine if restorative eye treatment (RET) and Inhance&#xD;
      with trihex technology used before and after blepharoplasty can lead to better skin quality&#xD;
      before undergoing blepharoplasty, and if these products will lead to less visible scarring&#xD;
      and faster healing after blepharoplasty.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Anticipated">May 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Collagen Content</measure>
    <time_frame>Up to 1 month prior to blepharoplasty surgery</time_frame>
    <description>Assessed from eyelid tissue samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Elastin Content</measure>
    <time_frame>Up to 1 month prior to blepharoplasty surgery</time_frame>
    <description>Assessed from eyelid tissue samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post operative bruising</measure>
    <time_frame>Up to 2 weeks post blepharoplasty surgery</time_frame>
    <description>Bruising will be assessed on a 1-5 scale with the higher score indicating more bruising.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post operative swelling</measure>
    <time_frame>Up to 2 weeks post blepharoplasty surgery</time_frame>
    <description>Swelling will be assessed on a 1 to 5 scale with the higher score indicating more swelling</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Eyelid Dermatochalasis</condition>
  <condition>Dermatochalasis</condition>
  <arm_group>
    <arm_group_label>RET Treated Eye Plus INhance Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to receive the restorative eye treatment (RET) intervention on either the left or right eyelid will administer the RET cream on the eyelid daily for 4 consecutive weeks prior to scheduled standard of care (SOC) blepharoplasty. After surgery, participants will receive INhance with Trihex technology applied to both eyelids daily for 10 consecutive days post surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RET Untreated eye Plus INhance Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to not receive the RET intervention will not receive any intervention prior to scheduled standard of care (SOC) blepharoplasty. After surgery, participants will receive INhance with Trihex technology applied to both eyelids daily for 10 consecutive days post surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Restorative Eye Treatment (RET) cream</intervention_name>
    <description>RET cream will be applied topically to either the left of right eyelid once daily for 4 consecutive weeks.</description>
    <arm_group_label>RET Treated Eye Plus INhance Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>INhance with Trihex Technology</intervention_name>
    <description>INhance will be applied topically to both eyelids once daily for 10 consecutive days after the SOC blepharoplasty surgery.</description>
    <arm_group_label>RET Treated Eye Plus INhance Group</arm_group_label>
    <arm_group_label>RET Untreated eye Plus INhance Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women who are about to have blepharoplasty at the Bascom Palmer Eye Institute&#xD;
             by Dr. Wendy Lee.&#xD;
&#xD;
          2. Men and women with no known medical conditions that, in the investigator's opinion,&#xD;
             may affect wound healing and interfere with study participation (e.g. diabetes, skin&#xD;
             disorder etc.).&#xD;
&#xD;
          3. Participants willing to provide consent for photographic release.&#xD;
&#xD;
          4. Participants must not be using any new skincare products, other than the study&#xD;
             products provided, on the treatment area for the duration of the study.&#xD;
&#xD;
          5. Participants willing to avoid extended periods of sun exposure and all use of tanning&#xD;
             beds for the duration of the study.&#xD;
&#xD;
          6. Participants must be willing to refrain from any other treatments or procedures to the&#xD;
             treatment area during the duration of the study.&#xD;
&#xD;
          7. 18 years old or older.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any dermatological disorder or poor health, which in the investigator's opinion, may&#xD;
             interfere with the accurate evaluation of the participants' skin characteristics or&#xD;
             inhibit wound healing.&#xD;
&#xD;
          2. Participants who have demonstrated a previous hypersensitivity reaction to any of the&#xD;
             ingredients of the study products.&#xD;
&#xD;
          3. Participants that have been using topical products around their upper or lower eyes&#xD;
             within 30 days.&#xD;
&#xD;
          4. Participants who are, in the opinion of the investigator, unwilling or unable to&#xD;
             comply with the requirements of the protocol.&#xD;
&#xD;
          5. Pregnant or lactating participants will be excluded, as well as participants planning&#xD;
             on becoming pregnant during the study duration.&#xD;
&#xD;
          6. Participants with recent excessive exposure to sunlight or artificial UV light (e.g.:&#xD;
             use of tanning beds/booths and/or sunbathing).&#xD;
&#xD;
          7. A participant with a history of keloids or hypertrophic scars.&#xD;
&#xD;
          8. Participants known to harbour a blood borne disease (e.g. Hepatitis A Virus (HAV),&#xD;
             Hepatitis B Virus (HBV), Hepatitis C Virus (HCV ), HIV)&#xD;
&#xD;
          9. Special populations: Prisoners, Pregnant women, Adults unable to consent, Individuals&#xD;
             who are not yet adults.&#xD;
&#xD;
         10. Have any condition that, in the opinion of the investigator, would compromise the&#xD;
             well-being of the patient or the study or prevent the patient from meeting or&#xD;
             performing study requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wendy W Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oded Ohana, MD</last_name>
    <phone>(305) 326-6000</phone>
    <email>oxo135@miami.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bascom Palmer Eye Institute, University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oded Ohana, MD</last_name>
      <phone>305-326-6000</phone>
      <email>oxo135@miami.edu</email>
    </contact>
    <investigator>
      <last_name>Wendy Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Reivitis A, Karimi K, Griffiths C, Banayan A. A single-center, pilot study evaluating a novel TriHex peptide- and botanical-containing eye treatment compared to baseline. J Cosmet Dermatol. 2018 Jun;17(3):467-470. doi: 10.1111/jocd.12542. Epub 2018 Apr 16.</citation>
    <PMID>29663676</PMID>
  </results_reference>
  <results_reference>
    <citation>Widgerow AD, Jacob C, Palm MD, Garruto JA, Bell M. Developing a Topical Adjunct to Injectable Procedures. J Drugs Dermatol. 2020 Apr 1;19(4):398-404. doi: 10.36849/JDD.2020.5016.</citation>
    <PMID>32272517</PMID>
  </results_reference>
  <results_reference>
    <citation>Widgerow AD, Jiang LI, Calame A. A single-center clinical trial to evaluate the efficacy of a tripeptide/hexapeptide antiaging regimen. J Cosmet Dermatol. 2019 Feb;18(1):176-182. doi: 10.1111/jocd.12507. Epub 2018 Mar 4.</citation>
    <PMID>29504212</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 11, 2021</study_first_submitted>
  <study_first_submitted_qc>August 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2021</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Wendy Lee</investigator_full_name>
    <investigator_title>Professor of Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>Blepharoplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cutis Laxa</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

